Effectivness of pegylated interferon alfa 2a and ribavirin for chronic hepatitis C in clinical practice;Efectividad del interferón peguilado alfa 2a más ribavirina para la hepatitis crónica C en la práctica

Acta Gastroenterologica Latinoamericana

Volumn 40, Issue 2, 2010, Pages 117-121

  Hernández, Nelia ^a   Mescia, Germán ^b   Pollio, Carmen ^b   Robaina, Gabriela ^b   Quintana, Laura ^a   Bianchi, Carla ^c  

^a Hospital de Clinicas   (Uruguay)

^b Hospital Maciel   (Uruguay)

^c Sanatorio SEMM Mautone   (Uruguay)

Author keywords

Chronic hepatitis C; Pegylated interferon; Ribavirin; Sustained virological response

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ARTICLE; ASTHENIA; CLINICAL PRACTICE; DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; DRUG WITHDRAWAL; ERADICATION THERAPY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PANIC; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; TUBERCULOUS PLEURISY; UROSEPSIS;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RETROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 77953778260     PISSN: 03009033     EISSN: 03009033     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002-June 10-12, 2002. Hepatology 2002;36:S3-S20.
2. Davis GL. Monitoring of viral levels during therapy of hepatitis C. Hepatology 2002:36;S145-S151.
3. Manns MP, McHutchison J, Gordon S, Rustgi V, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferón alfa-2b plus ribavirin compared with interferón plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965. (Pubitemid 32913521)
4. Fried M, Shiffman M, Reddy R, Smith C, Marinos G, Gonçales F, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferón alfa 2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
5. Heathcote EJ, Shiffman ML, Cooksley GE, Dusheiko GM, Lee SS, Balart L, Reindollar R, Reddy RK, Wright TL, Lin A, Hoffman J, De Pamphilis J. Peginterferón alfa 2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-1680.
6. Piai G, Scalice E, Focareta R, Terracciano F, Romana de Filippo F, Forte G. From trials to a real hospital setting: effectiveness of pegylated interferón-alfa-2b/ribavirin combination therapy for naïve chronic hepatitis C patients. Dig Dis Sci 2006;51:1619-1626.
7. Craxi A, Piccinino F, Alberti A, Ascione A, Rizzetto M, Iannacone C, Sarracino M. Predictors of SVR in naive HCV G1 patients in real life practice: The Probe. J Hepatol 2008;48:S291.
8. Lee S, Bain V, Peltekian K, Krajden M, Yoshida E, Deschenes M, Heathcote J, Bailey RJ, Simonvi S, Sherman M, Canadian Pegasys Study Group treating chronic hepatitis C with pegylated interferón alfa-2a (40 KD) and ribavirin in clinical practice. Aliment Pharmacol Ther 2006;23:397-408.
9. Njouom R, Tagni Sartre M, Timba I, Nerrienet E, Tchendjou P, Pasquier C, Rousset D. Efficacy and safety of peginterferon alpha 2a/ribavirin in treatment-naïve Cameroonian patients with chronic hepatitis C. J Med Virol 2008;80:2079-2085.
10. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, Sarrazin C, Harvey J, Brass C, Albrecht J. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004;40:993-999.
11. Borroni G, Andreoletti M, Casiraghi MA, Cerianis R, Guerzoni P, Omazzi B, Terreni N, Salerno F. Effectiveness of pegylated interferon/ribavirin combination in "real world" patientes with chronic hepatitis C virus infection. Aliment Pharmacol Ther 2008;27:790-797.
12. Franchini M, Mengoli C, Veneri D, Mazzi R, Lippi G, Cruciani M. Treatment of chronic hepatitis C in haemophilic patients with interfeon and ribavirin: a meta-analysis. J Antimicrob Chemother 2008;61:1191-1200.